U.S. Food and Drug Administration Approves Portola

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
1,779
U.S. Food and Drug Administration Approves Portola Pharmaceuticals’ Prior Approval Supplement for Andexxa® Generation 2 Manufacturing Process

– Expands Patient Access to Andexxa, the First and Only Antidote for Reversal of  the Factor Xa Inhibitors Rivaroxaban or Apixaban –

– Full Commercial Launch to Begin January 2019 –

SOUTH SAN FRANCISCO, Calif., Dec. 31, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Prior Approval Supplement (PAS) for its large-scale, second generation Andexxa ® [coagulation factor Xa (recombinant), inactivated-zhzo], allowing for broad commercial launch in the United States.

Andexxa received both U.S. Orphan Drug and FDA Breakthrough Therapy designations and was initially approved on May 3, 2018 under the FDA's Accelerated Approval pathway. It is the first and only antidote indicated for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

“It is clear from the response to the Andexxa Early Supply Program that there is significant need for a specific reversal agent that can address life-threatening bleeding associated with the use of the Factor Xa inhibitors apixaban and rivaroxaban,” said Scott Garland, Portola’s president and chief executive officer. "We are pleased to now be able to stock hospitals nationwide and serve all patients in the U.S. who could benefit from the potential life-saving impact of Andexxa.”

The use of Factor Xa inhibitors is rapidly growing because of their efficacy and safety profile compared to enoxaparin and warfarin in preventing and treating thromboembolic conditions such as stroke, pulmonary embolism and venous thromboembolism (VTE). This growth has come with a related increase in the incidence of hospital admissions and deaths related to bleeding, the major complication of anticoagulation. In the U.S. alone in 2017, there were approximately 140,000 hospital admissions attributable to Factor Xa inhibitor-related bleeding.

The Company will provide additional details on the commercial launch plans for Andexxa during its annual corporate webcast scheduled for Tuesday, January 8, at 7:00 a.m. PT (10:00 a.m. ET). The live webcast will be available on the Company's website at www.portola.com .

IMPORTANT INFORMATION FOR ANDEXXA [coagulation factor Xa (recombinant), inactivated-zhzo]

BOXED WARNING: THROMBOEMBOLIC RISKS, ISCHEMIC RISKS, CARDIAC ARREST AND SUDDEN DEATHS

See full prescribing information for complete boxed warning

Treatment with Andexxa has been associated with serious and life ‑ threatening adverse events, including:

  • Arterial and venous thromboembolic events
  • Ischemic events, including myocardial infarction and ischemic stroke
  • Cardiac arrest
  • Sudden deaths

Monitor for thromboembolic events and initiate anticoagulation when medically appropriate. Monitor for symptoms and signs that precede cardiac arrest and provide treatment as needed.

Indication Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo] is a recombinant modified human Factor Xa (FXa) protein indicated for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

This indication is approved under accelerated approval based on the change from baseline in anti-FXa activity in healthy volunteers. An improvement in hemostasis has not been established. Continued approval for this indication may be contingent upon the results of studies to demonstrate an improvement in hemostasis in patients.

Limitation of Use Andexxa has not been shown to be effective for, and is not indicated for, the treatment of bleeding related to any FXa inhibitors other than apixaban or rivaroxaban.

SELECT IMPORTANT SAFETY INFORMATION

Thromboembolic and Ischemic Risk

The thromboembolic and ischemic risks were assessed in 185 patients who received the Generation 1 product and in 124 patients who received the Generation 2 product. The median time to first event was six days, and patients were observed for these events for 30 days following Andexxa infusion. Of the 86 patients who received Generation 1 product and were re-anticoagulated prior to a thrombotic event, 11 (12.7%) patients experienced a thromboembolic event, ischemic event, cardiac event or death.

Monitor patients treated with Andexxa for signs and symptoms of arterial and venous thromboembolic events, ischemic events, and cardiac arrest. To reduce thromboembolic risk, resume anticoagulant therapy as soon as medically appropriate following treatment with Andexxa.

The safety of Andexxa has not been evaluated in patients who experienced thromboembolic events or disseminated intravascular coagulation within two weeks prior to the life-threatening bleeding event requiring treatment with Andexxa. Safety of Andexxa also has not been evaluated in patients who received prothrombin complex concentrates, recombinant Factor VIIa, or whole blood products within seven days prior to the bleeding event.

Re-elevation or Incomplete Reversal of Anti-FXa Activity The time course of anti-FXa activity following Andexxa administration was consistent among the healthy volunteer studies and the ANNEXA-4 study in bleeding patients. Compared to baseline, there was a rapid and substantial decrease in anti-FXa activity corresponding to the Andexxa bolus. This decrease was sustained through the end of the Andexxa continuous infusion. The anti-FXa activity returned to the placebo levels approximately two hours after completion of a bolus or continuous infusion. Subsequently, the anti-FXa activity decreased at a rate similar to the clearance of the FXa inhibitors.

Thirty-eight patients who received the Generation 1 product were anticoagulated with apixaban and had baseline levels of anti-FXa activity > 150 ng/mL. Nineteen of these 38 (50%) patients experienced a > 93% decrease from baseline anti-FXa activity after administration of Andexxa. Eleven patients who were anticoagulated with rivaroxaban had baseline anti-FXa activity levels > 300 ng/mL. Five of the 11 patients experienced a > 90% decrease from baseline anti-FXa activity after administration of Andexxa. Anti-FXa activity levels for patients who received the Generation 2 product were not available.

Adverse Reactions The most common adverse reactions (≥ 5%) in patients receiving Andexxa were urinary tract infections and pneumonia.

The most common adverse reactions (≥ 3%) in healthy volunteers treated with Andexxa were infusion-related reactions.

Immunogenicity As with all therapeutic proteins, there is potential for immunogenicity. Using an electrochemiluminescence (ECL)-based assay, 145 Generation 1 Andexxa-treated healthy subjects were tested for antibodies to Andexxa as well as antibodies cross-reacting with Factor X (FX) and FXa.  Low titers of anti-Andexxa antibodies were observed in 26/145 healthy subjects (17%); 6% (9/145) were first observed at Day 30 with 20 subjects (14%) still having titers at the last time point (days 44 to 48). To date, the pattern of antibody response in patients in the ANNEXA-4 study has been similar to that observed in healthy volunteers with 6% (6/98) of the patients having antibodies against Andexxa. None of these anti-Andexxa antibodies were neutralizing. No antibodies cross-reacting with FX or FXa were detected in healthy subjects (0/145) or in bleeding patients (0/98) to date. There is insufficient data to assess for the presence of anti-Andexxa antibodies for subjects received the Generation 2 product.

Detection of antibody formation is highly dependent on the sensitivity and specificity of the assay.  Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.  For these reasons, comparison of the incidence of antibodies to Andexxa with the incidence of antibodies to other products may be misleading.

About Portola Pharmaceuticals, Inc. Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Andexxa ® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, and Bevyxxa ®  (betrixaban), the first and only oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness. The company also is advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers.

Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, our intention to conduct a broad commercial launch of Andexxa in the United States and increase patient access to Andexxa. Risks that contribute to the uncertain nature of the forward-looking statements include: the risk that physicians, patients and payers may not see the benefits of utilizing Andexxa or Bevyxxa for the indications which they are approved; our ability to continue to manufacture our products and to expand approved manufacturing facilities; the possibility of unfavorable results from additional clinical trials involving Andexxa; the risk that the EMA may not approve Andexxa in the currently anticipated timelines or at all, and that any marketing approvals or reimbursement limitations may have significant limitations on its use; the risk that we may not obtain additional regulatory approvals necessary to expand approved indications for Andexxa; our expectation that we will incur losses for the foreseeable future and will need additional funds to finance our operations; the accuracy of our estimates regarding expenses and capital requirements; our ability to successfully build a hospital-based sales force and commercial infrastructure; our ability to obtain and maintain intellectual property protection for our product candidates; and our ability to retain key scientific or management personnel. These and other risks and uncertainties are described more fully in our most recent filings with the Securities and Exchange Commission, including our most recent quarterly report on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:                  Cara Miller                             Portola Pharmaceuticals IR@portola.com

Media Contact: Julie Normart Pure Communications jnormart@purecommunications.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Commodity Rout Tests a Market Already Short on Nerve

Updated Category News Views 80

Some weeks the tape merely wobbles; this one started throwing furniture. By midday Wednesday, traders were staring at sharp declines in gold, silver, crude and copper while the major equity benchmarks remained underwater for the week. That is an unpleasant combination. When growth-sensitive commodities and the usual hard-asset hiding places are all getting sold,...

Continue Reading
Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 59

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 150

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading
Happiest Minds Extends Absa Banking Platform Reach

Updated Category News Views 34

Mauritius just handed Happiest Minds a useful, if modest, banking-tech scorecard. On November 19, 2026, the company said its cloud-native Arttha platform had been deployed to support selected capabilities within Spark by Absa, a digital banking and lifestyle app from Absa Bank (Mauritius). This is not the sort of announcement that lets anybody pencil in a giant revenue...

Continue Reading
Securitize Tests the IPO Clock With Anthropic Tokens

Updated Category News Views 15

Anthropic did not even get a full trading day to itself before the tokenization crowd arrived. Securitize says Anthropic stock became available through Securitize Stocks on Solana on the company’s first day as a public company, a loud little signal that the old IPO playbook is being prodded from the edges. For investors, this is not merely another crypto-flavored...

Continue Reading
SwitchBot's Black Friday Sale Tests Smart Home Demand

Updated Category News Views 90

Holiday gadget season is where clever home-tech pitches either earn their keep or gather dust in a warehouse. SwitchBot is coming into Black Friday 2026 with discounts of up to 50% on select products, running from November 19 through Cyber Monday on November 30. The lineup is broad enough to matter: decorative color E Ink frames, automated curtains and blinds, an indoor...

Continue Reading
CSTS Award Highlights Its U.S. Expansion Ambitions

Updated Category News Views 51

A chamber-of-commerce trophy will not fill an arena or book a corporate travel contract, but it can tell you who is pushing hard for a seat at the table. CSTS Enterprises has picked up the New Jersey Chinese-American Chamber of Commerce's 2026 Corporate Achievement Award, its first major public U.S. recognition since placing its global headquarters in New York City. For a...

Continue Reading
Housing's Value Equation Is Getting More Complicated

Updated Category News Views 100

A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...

Continue Reading
Endeavor Metals Makes Its Case for Clearer Bullion

Updated Category News Views 61

Gold buyers do not need another velvet-rope sales pitch; they need the math before the handshake. Endeavor Metals Group, a West Palm Beach dealer established in 2013, is pitching something more useful than grand prophecy: a staffed, consultative route into physical gold, silver, platinum, palladium, bullion and collectible coins. In a business where shiny inventory can...

Continue Reading
IDEMIA Lands Sweden's Critical 5G Connectivity Job

Updated Category News Views 85

A hospital monitor going dark because a device was misprovisioned is not the kind of connectivity hiccup anybody gets to shrug off. That is why IDEMIA Secure Transactions winning the Region Västra Götaland assignment deserves more attention than the usual telecom plumbing announcement. The region is building what it calls Sweden's largest private 5G network, and the job...

Continue Reading

Top 5 Most Recently Viewed Articles

Business Jet Steals the Spotlight with Starlink Installation

Updated Category News Views 350

Business Jet Achieves Significant Milestone with Starlink Business Jet has proudly completed the first installation of Starlink on the Embraer Legacy 600 certification aircraft. This innovative achievement signifies a major step in enhancing the inflight connectivity experience for clients, marking the Legacy 600 as a pioneer aircraft equipped with Starlink capabilities....

Continue Reading
Understanding the Importance of Snow Removal for Roof Safety

Updated Category News Views 166

Understanding the Importance of Roof Snow Removal When it comes to maintaining the safety of your home during winter, one crucial task often overlooked is roof snow removal. Roofing expert John Kolarik from Mariage Roofing shares valuable insights on why homeowners should be proactive about this important aspect of winter maintenance. Removing snow from roofs not only...

Continue Reading
Teck Resources Plans Significant Share Buyback Initiative

Updated Category News Views 126

Teck Resources Limited's Normal Course Issuer Bid Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) has exciting news as it prepares to initiate a normal course issuer bid aimed at repurchasing its Class B subordinate voting shares. With the Toronto Stock Exchange’s approval, Teck is set to purchase up to 40 million of these shares, equating to roughly 7.9% of...

Continue Reading
SR Bancorp Sees Fluctuations in Quarterly Income Performance

Updated Category News Views 192

Introduction to SR Bancorp, Inc. SR Bancorp, Inc. (NASDAQ: SRBK), the holding company for Somerset Regal Bank, has recently published its quarterly financial results, reflecting changes in net income and asset growth. In the most recent quarter, the company demonstrated resilience and adaptability amidst fluctuating market conditions. Net Income Overview Financial Results...

Continue Reading
Reddit Inc's Stock Surges: Navigating Mispricing and Strategies

Updated Category News Views 146

Reddit Inc Experiences Remarkable Stock Surge After being under pressure for much of the spring, shares of Reddit Inc (NYSE: RDDT) have rebounded dramatically. The stock experienced a surge of over 50% within a span of just two weeks, decisively breaking out of its previous trading range and reaching all-time highs. This notable rebound is striking, especially considering...

Continue Reading